Abba Medix Receives MMPR Final Review Notice from Health Canada

Toronto, Ontario--(Newsfile Corp. - October 14, 2015) - In an important milestone for Abba Medix Group Inc. (CSE: ABA) ("The parent company"), Abba Medix Corp. has received notification from Health Canada that its MMPR license application has advanced to the final review stage, the last step before pre-license inspection.

"This is a great and much-anticipated day for the company, validating everything that we have been working towards," said Abba Medix CEO Ray Rasouli. "While waiting for this notice, the company has continued to aggressively pursue multiple alternative opportunities in the medical marijuana sector and will provide updates as soon as they are available." These opportunities remain aligned with Abba's original goal of delivering shareholders value through a multi-faceted and fully integrated medical marijuana business approach, with industry leadership as the end result.

During this final review stage, the application will be thoroughly reviewed by Health Canada to validate the information and documentation provided by Abba Medix Corp, including physical security plans for its state-of-the-art MMPR facility, completed in 2014.

About Abba Medix Group Inc.

Abba Medix Group Inc. (CSE: ABA) is the parent company of Abba Medix Corp; a purveyor of fine medical marijuana in Canada. In compliance with Health Canada's regulations, the company's goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated medical marijuana marketplace. Abba's mission is to find, acquire or create joint venture opportunities in patient focused medical marijuana related companies, products, organizational events, sponsorships, educational training, and research and development within medical marijuana sector. For more information please visit www.abbamedix.com.

Cautionary Statements Regarding Forward-Looking Information

Certain statements within this press release relating to the company and constitute "forward-looking statements," within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and / or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are "forward-looking statements." Such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including production and / or sales of medical marijuana, quantities of future medical marijuana production, anticipated revenues in connection with such sales, the overall projected size of the market, completion and / or expansion of production facilities, and other information that is based on forecasts of future results, estimates of production not yet determinable, and other key management assumptions. Actual results may differ materially from those expressed or implied by such forward-looking statements and involve risk and uncertainties relating to the Company's historical experience with medical marijuana operations, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, and other uninsured risks. The company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Further, there can be no assurance that Abba Medix Corp's medical marijuana license application will be approved by Health Canada, or that any prospective projects in the industry will be successfully completed. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

For further information please contact:

Ray Ahmad Rasouli
Chief Executive Officer
Abba Medix Group Inc.
Tel: (905) 492-9420